[HTML][HTML] Striatal dopamine neurotransmission: regulation of release and uptake

D Sulzer, SJ Cragg, ME Rice - Basal ganglia, 2016 - Elsevier
Dopamine (DA) transmission is governed by processes that regulate release from axonal
boutons in the forebrain and the somatodendritic compartment in midbrain, and by …

Adenosine receptors: expression, function and regulation

S Sheth, R Brito, D Mukherjea, LP Rybak… - International journal of …, 2014 - mdpi.com
Adenosine receptors (ARs) comprise a group of G protein-coupled receptors (GPCR) which
mediate the physiological actions of adenosine. To date, four AR subtypes have been …

Astrocyte molecular signatures in Huntington's disease

B Diaz-Castro, MR Gangwani, X Yu… - Science translational …, 2019 - science.org
Astrocytes are implicated in neurodegenerative disorders and may contribute to striatal
neuron loss or dysfunction in Huntington's disease (HD). Here, we assessed striatal …

Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits

JD Salamone, M Correa, A Farrar, SM Mingote - Psychopharmacology, 2007 - Springer
Background Over the last several years, it has become apparent that there are critical
problems with the hypothesis that brain dopamine (DA) systems, particularly in the nucleus …

The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA,“ecstasy”)

AR Green, AO Mechan, JM Elliott, E O'Shea… - Pharmacological …, 2003 - Elsevier
Abstract The amphetamine derivative (±)-3, 4-methylenedioxymethamphetamine (MDMA,
ecstasy) is a popular recreational drug among young people, particularly those involved in …

Adenosine and brain function

BB Fredholm, JF Chen, RA Cunha… - Int Rev …, 2005 - books.google.com
A. Cellular and Subcellular Localization B. Pharmacological Tools to Study Adenosine
Receptors C. Signaling Via Adenosine Receptors D. Regulation of Receptor Expression and …

Purinergic signalling: from normal behaviour to pathological brain function

G Burnstock, U Krügel, MP Abbracchio, P Illes - Progress in neurobiology, 2011 - Elsevier
Purinergic neurotransmission, involving release of ATP as an efferent neurotransmitter was
first proposed in 1972. Later, ATP was recognised as a cotransmitter in peripheral nerves …

[HTML][HTML] Adenosine receptors and brain diseases: neuroprotection and neurodegeneration

CV Gomes, MP Kaster, AR Tomé, PM Agostinho… - … et Biophysica Acta (BBA …, 2011 - Elsevier
Adenosine acts in parallel as a neuromodulator and as a homeostatic modulator in the
central nervous system. Its neuromodulatory role relies on a balanced activation of inhibitory …

Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade

RA Cunha - Purinergic signalling, 2005 - Springer
Adenosine is a neuromodulator that operates via the most abundant inhibitory adenosine A
1 receptors (A 1 Rs) and the less abundant, but widespread, facilitatory A 2A Rs. It is …

Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson's disease

P Jenner, A Mori, SD Aradi… - Expert Review of …, 2021 - Taylor & Francis
Introduction It is now accepted that Parkinson's disease (PD) is not simply due to
dopaminergic dysfunction, and there is interest in developing non-dopaminergic …